Rephonic
Artwork for Oncology On The Go

Oncology On The Go

CancerNetwork
Clinical Trials
Immunotherapy
Multiple Myeloma
Breast Cancer
Cancer
CAR T-Cell Therapy
Pancreatic Cancer
Renal Cell Carcinoma
Lymphoma
Cancer Care
Cytokine Release Syndrome
Kidney Cancer
Oncology
Bispecific Antibodies
Mental Health
Chemotherapy
Liquid Biopsy
FDA
Non-Small Cell Lung Cancer
Glioblastoma

Oncology On The Go is a weekly podcast that talks to authors and experts to thoroughly examine featured articles in the journal ONCOLOGY and review other challenging treatment scenarios in the cancer field from a multidisciplinary perspective. Our discussions also offer timely insight into topics ranging from recent FDA approvals to relevant research presented at major oncology conferences. As th... more

PublishesWeeklyEpisodes253Founded6 years ago
Number of ListenersCategory
Science

Listen to this Podcast

Artwork for Oncology On The Go

Latest Episodes

In the newest edition of Oncology On the Go, Joshua Richter, MD, and Marco Davila, MD, PhD, spoke about the current multiple myeloma treatment landscape and highlighted practical considerations for administering CAR T-cell therapy to patients. Their ... more

At the 2026 National ICE-T Conference in Orlando, CancerNetwork® sat down with a variety of expert researchers and clinicians to discuss the latest developments in immune effector therapy across different hematologic oncology populations. Sessions at... more

Following the FDA approval of allogeneic regulatory T cell–containing immunotherapy with hematopoietic stem and progenitor cell (HSPC) and T cells-vldq (Tregzi; Orca-T), CancerNetwork® spoke with Wendy Stock, MD, about what this decision means for th... more

Experts discuss diagnosing and treating insomnia in patients with cancer through methods like sleep hygiene, CBT-I, and pharmacotherapy.

Insomnia is one of the most common symptoms oncologists are asked to manage, yet it’s often treated reactively w... more

In this episode of Oncology On the Go, CancerNetwork® spoke with Kim Stravers, an International End-of-Life Doula Association (INELDA)–certified end-of-life doula, educator, and trainer based in the Phoenix Valley, to explore how death doulas support... more

Experts discuss the evolving frontline CML treatment landscape, the impact of asciminib, and clinical strategies for achieving treatment-free remission.

Once considered a terminal diagnosis, chronic myeloid leukemia (CML) in chronic phase has been f... more

In this episode of Oncology On the Go, CancerNetwork® joined Matthew Matasar, MD, chief of the Division of Blood Disorders at Rutgers Cancer Institute/Jack & Sheryl Morris Cancer Center, and professor of medicine at Rutgers Robert Wood Johnson Medica... more

In a special edition of Oncology On the Go, Chinmay Jani, MD, joined CancerNetwork® in the studio to speak about different research initiatives he is involved with across precision oncology. He discussed ongoing work dedicated to validating and apply... more

Key Facts

Accepts Guests
Contact Information
Podcast Host
Number of Listeners
Find out how many people listen to this podcast per episode and each month.

Similar Podcasts

People also subscribe to these shows.

Recent Guests

Benjamin Diamond
Speaker, University of Miami Miller School of Medicine
University of Miami Miller School of Medicine
Episode: S1 Ep226: Unraveling Immune Effector Therapy Advances Across Hematologic Oncology
Tiba Al Sagheer
Clinical pharmacist
Baptist Health South Florida
Episode: S1 Ep226: Unraveling Immune Effector Therapy Advances Across Hematologic Oncology
Nikesh Shah
Physician (debate participant)
Tampa General Hospital
Episode: S1 Ep226: Unraveling Immune Effector Therapy Advances Across Hematologic Oncology
Carlos Silva
Physician (debate participant)
Memorial Healthcare System
Episode: S1 Ep226: Unraveling Immune Effector Therapy Advances Across Hematologic Oncology
Dr. Wendy Stock
Physician at University of Chicago Medicine Comprehensive Cancer Center
University of Chicago Medicine Comprehensive Cancer Center
Episode: S1 Ep225: How Will Orca-T Impact the Hematologic Oncology Paradigm?
Virginia O'Brien
Expert in insomnia and sleep hygiene
Episode: S1 Ep224: Managing Insomnia in Cancer Care: Sleep Hygiene, CBT-I, and Medications
Kim Stravers
Inelda certified death doula
Inelda / National End-Of-Life Doula Alliance (NEDA)
Episode: S1 Ep222: How Does a Death Doula Support Patients With Cancer?
Jorge Cortes
Guest expert, CML specialist
O'Neal Cancer Center, University of Alabama at Birmingham
Episode: S1 Ep223: Optimizing Frontline Selection and Treatment-Free Remission in CML
Matthew Matasar
Chief of the Division of Blood Disorders at Rutgers Cancer Institute
Rutgers Cancer Institute
Episode: S1 Ep221: Redefining Lymphoma Standards of Care: Top Datasets From ASCO and EHA 2026

Hosts

Russ Conroy
Host of Oncology On The Go, frequently guiding interviews and synthesizing clinical relevance.
Arianna Pelosi
Co-host, facilitates episodes and provides clinical context.
Ruscon Roy
Host contributing expert perspectives and clinical discussion.

Top Science Podcasts

Something You Should Know
Something You Should KnowMike Carruthers | OmniCast Media
Radiolab
RadiolabWNYC Studios
Hidden Brain
Hidden BrainHidden Brain, Shankar Vedantam
StarTalk Radio
StarTalk RadioNeil deGrasse Tyson
Big Ideas Lab
Big Ideas LabMission.org
Science Friday
Science FridayScience Friday and WNYC Studios
Sasquatch Chronicles
Sasquatch ChroniclesSasquatch Chronicles - Bigfoot Encounters
Are We Doomed?
Are We Doomed?NPR Network

Talking Points

Recent interactions between the hosts and their guests.

S1 Ep225: How Will Orca-T Impact the Hematologic Oncology Paradigm?
Q: The Precision T trial spanned AML, ALL, high-risk MDS, and mixed phenotype acute leukemia. Do you expect the benefit with Orca-T to be uniform across those diseases, or are there malignancies where reducing GVHD matters more?
Dr. Stock suggests that the answer is not clear, as subgroup analyses are limited by trial size, though graft-versus-leukemia effects generally favor myeloid malignancies; overall, the trial showed significant effects across populations but individual disease-level benefits remain uncertain.
S1 Ep225: How Will Orca-T Impact the Hematologic Oncology Paradigm?
Q: How do you position Orca-T against a PTCY backbone? Is this a replacement, a competitor for specific patients, or a different philosophy of graft engineering altogether?
The guest notes that Orca-T represents a different concept from PTCY, which is not graft engineering per se, and acknowledges that head-to-head prospective comparisons are needed to determine whether Orca-T or PTCY is superior in similar patient populations.
S1 Ep225: How Will Orca-T Impact the Hematologic Oncology Paradigm?
Q: What does this approval validate conceptually, and does it change how clinicians should think about allograft itself as a drug that can be engineered rather than just infused?
Dr. Stock explains that the approval validates years of graft manipulation work aimed at improving outcomes, with the major goals being reducing relapse and graft-versus-host disease, and it supports the view that the graft can be engineered to enhance safety and efficacy rather than being merely infused.
S1 Ep221: Redefining Lymphoma Standards of Care: Top Datasets From ASCO and EHA 2026
Q: Given the promising data surrounding Epcoridimab plus R-mini-CVP for frail patients, do you see this non-anthracycline, bispecific-driven approach completely replacing standard regimens in the frontline?
In the short term, not likely to replace standard regimens entirely, but there is clear momentum toward integrating bispecifics and non-anthracycline approaches for older or less fit patients, with ongoing trials aiming to move these strategies into frontline settings.
S1 Ep221: Redefining Lymphoma Standards of Care: Top Datasets From ASCO and EHA 2026
Q: So, my first one for you, a very general one, ASCO-specific. What in your opinion were the top abstracts? Were there any that particularly surprised you or stuck out?
Highlights centered on aggressive B-cell lymphoma management, with particular attention to the FrontMind trial and its implications for frontline regimens, plus encouraging data on strategies for elderly or frail patients and novel targets and mechanisms that may expand our therapeutic toolbox.

Audience Metrics

Listeners, social reach, demographics and more for this podcast.

Listeners per Episode
Gender Skew
Location
Interests
Professions
Age Range
Household Income
Social Media Reach

Frequently Asked Questions About Oncology On The Go

What is Oncology On The Go about and what kind of topics does it cover?

This show features in-depth conversations with leading oncology clinicians, researchers, and thought leaders who discuss high-impact topics in cancer treatment, research updates, and the practical implications of new data. Episodes frequently center on immunotherapy, targeted therapies, cell therapies, and emerging biomarkers, often tying trial results and conference takeaways to real-world practice, patient care, and health-system implementation. A notable strength is the multidisciplinary lens—discussants span medical oncology, hematology, translational biology, and supportive care—making it useful for listeners who want clinically relevant insights, actionable takeaways, and context for evolving standards of care. The format often includ... more

Where can I find podcast stats for Oncology On The Go?

Rephonic provides a wide range of podcast stats for Oncology On The Go. We scanned the web and collated all of the information that we could find in our comprehensive podcast database. See how many people listen to Oncology On The Go and access YouTube viewership numbers, download stats, audience demographics, chart rankings, ratings, reviews and more.

How many listeners does Oncology On The Go get?

Rephonic provides a full set of podcast information for three million podcasts, including the number of listeners. View further listenership figures for Oncology On The Go, including podcast download numbers and subscriber numbers, so you can make better decisions about which podcasts to sponsor or be a guest on. You will need to upgrade your account to access this premium data.

What are the audience demographics for Oncology On The Go?

Rephonic provides comprehensive predictive audience data for Oncology On The Go, including gender skew, age, country, political leaning, income, professions, education level, and interests. You can access these listener demographics by upgrading your account.

How many subscribers and views does Oncology On The Go have?

To see how many followers or subscribers Oncology On The Go has on Spotify and other platforms such as Castbox and Podcast Addict, simply upgrade your account. You'll also find viewership figures for their YouTube channel if they have one.

Which podcasts are similar to Oncology On The Go?

These podcasts share a similar audience with Oncology On The Go:

1. Two Onc Docs
2. OncLive® On Air
3. Oncology Brothers: Practice-Changing Cancer Discussions
4. Oncology Today with Dr Neil Love
5. This American Life

How many episodes of Oncology On The Go are there?

Oncology On The Go launched 6 years ago and published 253 episodes to date. You can find more information about this podcast including rankings, audience demographics and engagement in our podcast database.

How do I contact Oncology On The Go?

Our systems regularly scour the web to find email addresses and social media links for this podcast. We scanned the web and collated all of the contact information that we could find in our podcast database. But in the unlikely event that you can't find what you're looking for, our concierge service lets you request our research team to source better contacts for you.

Where can I see ratings and reviews for Oncology On The Go?

Rephonic pulls ratings and reviews for Oncology On The Go from multiple sources, including Spotify, Apple Podcasts, Castbox, and Podcast Addict.

View all the reviews in one place instead of visiting each platform individually and use this information to decide if a show is worth pitching or not.

How do I access podcast episode transcripts for Oncology On The Go?

Rephonic provides full transcripts for episodes of Oncology On The Go. Search within each transcript for your keywords, whether they be topics, brands or people, and figure out if it's worth pitching as a guest or sponsor. You can even set-up alerts to get notified when your keywords are mentioned.

What guests have appeared on Oncology On The Go?

Recent guests on Oncology On The Go include:

1. Benjamin Diamond
2. Tiba Al Sagheer
3. Nikesh Shah
4. Carlos Silva
5. Dr. Wendy Stock
6. Virginia O'Brien
7. Kim Stravers
8. Jorge Cortes

To view more recent guests and their details, simply upgrade your Rephonic account. You'll also get access to a typical guest profile to help you decide if the show is worth pitching.

Find and pitch the right podcasts

We help savvy brands, marketers and PR professionals to find the right podcasts for any topic or niche. Get the data and contacts you need to pitch podcasts at scale and turn listeners into customers.
Try it free for 7 days